

# FREDUN PHARMACEUTICALS LIMITED

*Compassionate Healthcare*



CIN No : L24239MH1987PLC043662

AUDITED FINANCIAL RESULTS FOR THE QUARTER & YEAR ENDED 31.03.2021

PARTICULARS	Rs. In Lakhs				
	Quarter Ended		Year Ended		
	Audited 31.03.2021	Unaudited 31.12.2020	Audited 31.03.2020	Audited 31.03.2021	Audited 31.03.2020
<b>1 Income from Operations</b>					
Net Sales / Income From Operation (Net of GST)	4112.27	4509.87	2442.06	13155.19	11029.86
2 Other Operating Income	125.70	46.91	88.28	373.80	298.99
3 Total income from operations (net)	4237.97	4556.78	2530.34	13528.99	11328.85
<b>4 Expenses</b>					
a) Cost of Material Consumed	3726.73	3650.55	2406.01	10060.41	8611.79
b) Cost of Material Consumed for R & D	16.89	12.77	17.95	47.39	67.22
c) Other R & D Expenses	(4.14)	0.00	3.39	0.00	0.00
d) Changes in inventories of finished goods, work-in-progress and stock in trade	(574.35)	69.78	(1061.71)	116.82	(504.27)
e) Manufacturing & Service Cost	180.96	117.76	138.55	477.02	528.89
f) Finance Costs	129.08	119.09	113.91	416.21	441.39
g) Employees benefits expenses	246.47	212.82	298.13	865.61	894.77
h) Depreciation and amortisation expenses	51.83	52.80	47.35	200.37	187.87
i) Other Expenses	363.77	187.55	528.88	908.13	851.73
Total expenses	4137.24	4423.12	2492.46	13091.96	11079.39
5 Profit/(Loss) from ordinary activities before exceptional items & tax (3-4)	100.73	133.66	37.88	437.03	249.46
6 Exceptional items / Prior Period Item	0.00	0.00	0.00	(116.37)	0.00
7 Profit/(Loss) from ordinary activities before tax (5-6)	100.73	133.66	37.88	320.66	249.46
8 Tax Expenses	28.02	0.00	59.27	119.20	59.27
9 Profit/(Loss) from continuing operations	72.71	133.66	(21.39)	201.46	190.19
10 Profit/(Loss) from discontinued operations	0.00	0.00	0.00	0.00	0.00
11 Tax Expense of discontinued operations	0.00	0.00	0.00	0.00	0.00
12 Profit/(Loss) from discontinued operations after tax	0.00	0.00	0.00	0.00	0.00
13 Profit/ (Loss) for the period	72.71	133.66	(21.39)	201.46	190.19
<b>14 Other comprehensive Income</b>					
A (i) Items that will not be re-classified to profit/ loss	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will not be re-classified to profit/ loss	0.00	0.00	0.00	0.00	0.00
B (i) Re measurement of post - employment benefit obligations	-0.24	0.00	0.00	-0.23	0.00
C (ii) Items that will be re-classified to profit / loss	0.00	0.00	0.00	0.00	0.00
(iii) Income tax relating to items that will be re-classified to profit/ loss	0.00	0.00	0.00	0.00	0.00
<b>Total Comprehensive Income for the year</b>	<b>72.47</b>	<b>133.66</b>	<b>(21.39)</b>	<b>201.23</b>	<b>190.19</b>
15 Paid up Equity Share Capital (Face Value of Rs-10/- each)	398.96	398.96	398.96	398.96	398.96
16 Reserves excluding Revaluation Reserves	3908.06	0.00	0.00	3908.06	3733.16
17 Earning per Share (EPS) (before & after extra ordinary items)					
- Basic/ Diluted Earning Per Share (Rs.)	1.82	3.35	(0.54)	5.05	4.77
<b>A 1) Public Shareholding</b>					
Number of shares	1913524	1913524	1913524	1913524	1913524
Percentage of shareholding	47.96	47.96	47.96	47.96	47.96
<b>2) Promoters and promotor group shareholding</b>					
a) Pledged/Encumbered					
- Number of shares	-	-	-	-	-
- Percentage of shares (as a % of total shareholding of Promoters and Promoter Group)	-	-	-	-	-
- Percentage of shares (as a % of total share capital of the Company)	-	-	-	-	-
b) Non-encumbered					
- Number of shares	2076110	2076110	2076110	2076110	2076110
- Percentage of shares (as a % of total shareholding of Promoters and Promoter Group)	100%	100%	100%	100%	100%
Company)	52.04	52.04	52.04	52.04	52.04



Office Address: Manoj Industrial Premises, G.D. Ambekar Marg, Wadala (W), Mumbai - 400 031, (INDIA)

Phone No.: 91-22- 4031 8111 Fax : 91-22-4031 8133

Factory Address: 14,15,16, Zorabian Industrial Complex, Vevoor, Palghar (E), Dist: Palghar - 401 404.

Phone No.: +917045957828, +917045957829, +917045957830, +917045956857

E-Mail: business@fredungroup.com Web: www.fredungroup.com

# FREDUN PHARMACEUTICALS LIMITED

*Compassionate Healthcare*

CIN No: L24239MH1987PLC043662



**NOTES:-**

1) The above results were taken on record by the Board Of Directors at the meeting held on 28.06.2021

2) Previous year's figures have been regrouped/rearranged wherever necessary.

3) During the quarter ended 31st Mar 2021 there are no investor's complaints pending & no investor's complaints were received by the company during this period.

4) Provision for deferred tax made on March 2021

5) The above result have already been approve by the Audit Comitee of the board

7) This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable. Beginning 1st April 2017, the Company has for the first time adopted Ind AS with a transition date of 1st April, 2016.

**8) Employee Benefit Expense**

Particular	Quarter Ended		Year Ended		
	Audited 31.03.2021	Unaudited 31.12.2020	Audited 31.03.2020	Audited 31.03.2021	Audited 31.03.2020
Break – up of Employee Benefit					
Salary & Wages	14,995,497.00	18,027,225.00	23,611,930.00	67,688,703.00	70,105,314.00
Director Remuneration	1,230,000.00	1,230,000.00	1,230,000.00	4,920,000.00	4,920,000.00
Contributionn to Provident and Other Funds	942,580.00	1,418,812.00	1,096,360.00	4,017,487.00	4,003,221.00
Share Base Payment to employees	0.00	0.00	0.00	0.00	0.00
Staff Welfare Expenses	182,737.00	606,141.00	789,781.00	2,571,166.00	2,127,555.00

**9) Gain/ Loss on account of Foreign Exchange Fluctuation (Included in other Income)**

Particular	Quarter Ended			Year Ended	
	31.03.2021	31.12.2020	31.03.2020	31.03.2021	31.03.2020
Gain / Loss on Account of Foreign Exchange Fluctuation ( Add in Other Income )	0.00	936,122.00	829,402.00	553,568.00	2,306,894.00
Loss on Account of Foreign Exchange ( Record In Indirect Expenses )	-553,588.00	0.00	0.00	0.00	0.00

Office Address: Manoj Industrial Premises, G.D. Ambekar Marg, Wadala (W), Mumbai - 400 031, (INDIA)

Phone No.: 91-22- 4031 8111 Fax : 91-22-4031 8133

Factory Address: 14,15,16, Zorabian Industrial Complex, Vevoor, Palghar (E), Dist: Palghar - 401 404.

Phone No.: +917045957828, +917045957829, +917045957830, +917045956857

E-Mail: business@fredungroup.com Web: www.fredungroup.com



# FREDUN PHARMACEUTICALS LIMITED

*Compassionate Healthcare*



CIN No : L24239MH1987PLC043662

## 10) Reconciliation of Net Profit between Previous GAAP and IND AS

Rs. in Lakhs

Quarter ended 31.03.2021			
	I- GAAP	transition to	IND -AS
<b>Income from Operations</b>			
Net Sales /IncomeFrom Operation (Net of GST)	4112.27	-	4112.27
Other Operating Income	125.70	-	125.70
Total income from operatoinis (net)	4237.97	-	4237.97
<b>Expenses</b>			
a) Cost of Material Consumed	3726.73	-	3726.73
b) Cost of Material Consumed for R & D	16.89	-	16.89
c) Other R & D Expenses	(4.14)	-	(4.14)
stock in trade	(574.35)	-	(574.35)
d) Manufacturing & Service Cost	180.96	-	180.96
e)Finance Costs	129.08	-	129.08
f) Employess benefits expenses	246.47	-	246.47
g) Depreciation and amortisation expenses	51.83	-	51.83
h)Provision for doubtful debts	0.00	-	0.00
i) Other Expenses	363.77	-	363.77
Total Expenditure	4137.24	-	4137.24
tax (3-4)	100.73	-	100.73
Exceptional items / Prior Period Item	0.00	-	0.00
Profit/(Loss) from ordinary activities before tax (5-6)	100.73	-	100.73
Tax Expenses	28.02	-	28.02
Profit/(Loss) from continuing operations	72.71	-	72.71
Profit/(Loss) from discontinued operations	0.00	-	0.00
Tax Expense of discontinued operations	0.00	-	0.00
Profit/(Loss) from discontinued operations after tax	0.00	-	0.00
Profit/ (Loss) for the period	72.71	-	72.71
Other comprehensive Income	0.00	-	0.00
Total Comprehensive Income for the period	72.71	-	72.71

11) Tax expenses impact of quarter 4th is considered in respective quater and earlier quarter impact of tax expenses has been considered on annual basis and shown under year eneded data

PLACE: MUMBAI

DATE : 28.06.2021

FOR FREDUN PHARMACEUTICALS LIMITED

MANAGING DIRECTOR & CFO  
FREDUN N. MEDHORA  
DIN : 01745348



Office Address: Manoj Industrial Premises, G.D. Ambekar Marg, Wadala (W), Mumbai - 400 031, (INDIA)

Phone No.: 91-22- 4031 8111 Fax : 91-22-4031 8133

Factory Address: 14,15,16, Zorabian Industrial Complex, Vevoor, Palghar (E), Dist: Palghar - 401 404.

Phone No.: +917045957828, +917045957829, +917045957830, +917045956857

E-Mail: business@fredungroup.com Web: www.fredungroup.com

# FREDUN PHARMACEUTICALS LIMITED

*Compassionate Healthcare*



CIN No : L24239MH1987PLC043662

STATEMENT OF ASSETS AND LIABILITIES		Rs. In Lakhs	
	Particulars	As at 31.03.2021	As at 31.03.2020
<b>A</b>	<b>EQUITY &amp; LIABILITIES</b>		
	<b>1 Shareholders' Funds</b>		
	a) Equity Share Capital	398.96	398.96
	b) Other Equity	3908.06	3733.17
	<b>Sub-total - Shareholders' Funds</b>	<b>4307.02</b>	<b>4132.13</b>
	<b>2 Share application money pending allotment</b>	-	-
	<b>3 Non Current Liabilities</b>		
	a) Borrowings	2911.08	1149.59
	b) Provisions	160.45	163.09
	c) Other non- Current liabilities	0.00	0.00
	d) Deferred Tax Liabilities (Net)	137.71	94.07
	<b>Sub-total - Non Current Liabilities</b>	<b>3209.24</b>	<b>1406.75</b>
	<b>4 Current Liabilities</b>		
	a) Financial Liabilities		
	1) Borrowings	1052.95	2340.64
	2) Trade Payables	5996.05	4622.31
	3) Other Financial Liabilities	2.47	1.86
	b) Other Current Liabilities	1481.56	1377.25
	c) Short term provisions	0.00	0.00
	d) Current tax liabilities ( Net)	112.55	256.87
	<b>Sub-total - Current Liabilities</b>	<b>8645.58</b>	<b>8598.93</b>
	<b>TOTAL EQUITY AND LIABILITIES</b>	<b>16161.84</b>	<b>14137.81</b>
<b>B</b>	<b>ASSETS</b>		
	<b>1) Non-current assets</b>		
	(a) Property , Plant and equipment	3032.47	3092.66
	(b) Capital work in Progress	0.00	0.00
	(c) Financial Assets	0.00	0.00
	1) Loans	0.00	0.00
	2) Other financial assets	68.27	58.41
	3) Other Intangible Assets	2.72	4.12
	(d) Non - Current Investment	0.28	0.28
	(e) Other non current assets	50.00	50.00
	<b>Sub-total - Non-current assets</b>	<b>3153.74</b>	<b>3205.47</b>
	<b>2) Current assets</b>		
	(a) Inventories	6757.45	5046.17
	(b) Financial assets	0.00	0.00
	(1) Investments	5.80	4.90
	(2) Trade and other receivable	4107.53	3897.40
	(3) Cash and cash equivalents	99.46	274.79
	(4) Bank Balance Other Than 3 above	13.36	31.11
	(5) Loans	72.60	15.38
	(6) Other financial assets	81.06	205.16
	(c) Other current Assets	1870.84	1457.43
	<b>Sub-total - Current assets</b>	<b>13008.10</b>	<b>10932.34</b>
	<b>TOTAL - ASSETS</b>	<b>16161.84</b>	<b>14137.81</b>

PLACE : MUMBAI  
DATE : 28.06.2021

FOR FREDUN PHARMACEUTICALS LIMITED

MANAGING DIRECTOR & CFO  
FREDUN N. MEDHORA  
DIN : 01745348



Office Address: Manoj Industrial Premises, G.D. Ambekar Marg, Wadala (W), Mumbai - 400 031, (INDIA)

Phone No.: 91-22- 4031 8111 Fax: 91-22-4031 8133

Factory Address: 14,15,16, Zorabian Industrial Complex, Veveor, Palghar (E), Dist: Palghar - 401 404.

Phone No.: +917045957828, +917045957829, +917045957830, +917045956857

E-Mail: business@fredungroup.com Web: www.fredungroup.com



**FREDUN PHARMACEUTICALS LTD.**

**CASH FLOW STATEMENT FOR THE YEAR ENDED 31st MARCH, 2021**

	<b>F.Y. 2020-2021</b>	<b>F.Y. 2019-2020</b>
<b>A) CASH FLOW FROM OPERATING ACTIVITIES:</b>		
NET PROFIT AFTER TAXATION	20,123,114.00	23,458,583.95
<u>ADJUSTMENTS FOR :</u>		
DEPRECIATION	20,037,450.34	18,787,338.70
INTEREST PAID	41,620,876.68	44,138,636.69
INTEREST RECEIVED	226,691.00	-677,023.50
CREDITORS WRITTEN BACK	12,723,901.46	1,013,636.51
	74,608,919.48	63,262,588.40
	94,732,033.48	86,721,172.35
<u>ADJUSTMENT TO OPERATING PROFIT</u>		
PRIOR PERIOD ADJUSTMENTS		
DEFERRED TAX LIABILITY	4,364,195.00	1,488,146.00
ADJUSTMENT FOR PROPOSED DIVIDEND TAX		
ADJUSTMENT FOR TAX PROVISION	7,555,000.00	-4,439,400.00
<b>OPERATING PROFIT BEFORE WORKING CAPITAL CHANGES</b>	<b>106,651,228.48</b>	<b>83,769,918.35</b>
<u>EFFECTS OF CHANGES IN WORKING CAPITAL ITEMS</u>		
<u>INCREASE / DECREASE IN :-</u>		
INVENTORY	-171,128,645.00	-96,816,224.00
INVESTMENTS	-90,000.00	-460,000.00
TRADE RECEIVABLES	-21,012,440.67	-150,123,048.05
LOANS & ADVANCES	-5,722,298.70	-252,626.89
OTHER CURRENT ASSETS	-41,341,600.48	-22,556,017.16
OTHER FINANCIAL ASSETS	12,409,478.28	232,924.99
OTHER FINANCIAL ASSETS	-986,000.00	-203,311.07
TRADE PAYABLES	137,374,192.31	104,840,356.38
OTHER CURRENT LIABILITIES	10,430,934.99	-11,068,085.21
OTHER NON CURRENT LIABILITIES		
OTHER NON CURRENT INVESTMENTS		
SHORT TERM PROVISION		
PROVISION FOR TAX	-21,987,153.00	4,342,900.00
RESERVES & SURPLUS	-2,634,132.87	-23,321,108.49
SHARE PREMIUM (RESERVES & SURPLUS)		
	-104,687,665.14	-195,384,239.50
	1,963,563.34	-111,614,321.15
<u>INCREASE / DECREASE IN :-</u>		
LONG TERM LOANS & ADVANCES		
LONG TERM PROVISIONS	-264,216.00	5,473,817.00
	-264,216.00	5,473,817.00
<b>NET CASH FLOW FROM OPERATING ACTIVITIES</b>	<b>1,699,347.34</b>	<b>-106,140,504.15</b>
<b>EFFECTS OF CHANGES IN NON CURRENT ITEMS</b>		
<b>OTHER NON CURRENT ASSETS</b>		-300,000.00
<b>NET ADJUSTED CASH FLOW FROM OPERATING ACTIVITIES</b>	<b>1,699,347.34</b>	<b>-106,440,504.15</b>
<b>B) CASH FLOW FROM INVESTING ACTIVITIES</b>		
PURCHASE OF FIXED ASSETS	-13,878,629.55	-14,927,954.53
CAPITAL WORK IN PROGRESS		
	-13,878,629.55	-14,927,954.53
	-12,179,282.21	-121,368,458.68
<b>C) CASH FLOW FROM FINANCING ACTIVITIES</b>		
<u>INCREASE / DECREASE IN ISSUE OF SHARE CAPITAL</u>		
<u>INCREASE / DECREASE IN LONG TERM BORROWINGS</u>		
176,149,773.20	8,567,633.87	
<u>INCREASE / DECREASE IN SHORT TERM BORROWINGS</u>		
-128,707,919.54	173,199,387.66	
INTEREST RECEIVED	226,691.00	677,023.50
INTEREST PAID	-41,620,876.68	-44,138,636.69
CREDITORS WRITTEN BACK	-12,723,901.46	-1,013,636.51
	-7,129,615.48	137,291,771.83
<b>NET INCREASE / DECREASE IN CASH</b>	<b>-19,308,897.69</b>	<b>15,923,313.15</b>
OPENING CASH & BANK BALANCE	30,590,577.97	14,667,264.82
<b>CLOSING CASH &amp; BANK BALANCE</b>	<b>11,281,680.28</b>	<b>30,590,577.97</b>



For Savla & Associates  
Chartered Accountants  
Firm Registration No - 109361W


  
Deepak G. Savla  
Partner  
Membership No - 043901  
UDIN No. : 21043901AAAAFF8104



Place - Mumbai  
Date :- 28th June 2021

For and on behalf of the Board of  
CIN No - L24239MH1987PLC043662  
For Fredun Pharmaceuticals Limited

  
Dr. (Mrs) Daulat N. Medhora  
Joint Managing Director  
DIN : 01745277

  
Mr. Fredun N. Medhora  
Managing Director & CFO  
DIN : 01745348



**Note:-**

- 1 The above Cash Flow Statement has been prepared under the indirect method set out in the Indian Accounting Standard (Ind AS) - 7 on
- 2 Direct taxes paid are treated as arising from operating activities and not bifurcated between investing and financing activities.
- 3 Figures in Bracket sign indicate cash outflow.
- 4 Previous year figures have been regrouped & recast, wherever necessary, to conform to the current year's classification.

FREDUN PHARMACEUTICALS LIMITED			
Standalone Balance Sheet for the year ended 31 March, 2021			
	Notes	As at 31 March, 2021	As at 31 March, 2020
<b>I ASSETS</b>			
<b>NON-CURRENT ASSETS</b>			
a) Property, Plant and Equipment	3	303,247,475.85	309,266,071.32
b) Capital Work-in-Progress		-	-
c) Other Intangible Assets	4	272,056.47	412,281.79
d) Financial assets			
i) Investments	5	27,600.00	27,600.00
ii) Loans		-	-
iii) Other Financial Assets	6	6,827,237.53	5,841,237.53
c) Other Non-current Assets	7	5,000,000.00	5,000,000.00
<b>Total non - current assets</b>		<b>315,374,369.85</b>	<b>320,547,190.64</b>
<b>CURRENT ASSETS</b>			
a) Inventories	8	675,745,389.00	504,616,744.00
b) Financial Assets			
i) Investments	9	580,000.00	490,000.00
ii) Trade and other receivables	10	410,752,878.52	389,740,437.85
iii) Cash and Cash Equivalents	11	9,945,476.26	27,479,231.55
iv) Bank Balance other than (iii) above	12	1,336,204.02	3,111,346.42
iv) Loans	13	7,259,802.00	1,537,503.30
v) Other Financial Assets	14	8,106,340.76	20,515,819.04
c) Other Current Assets	15	187,084,373.20	145,742,772.72
<b>Total current assets</b>		<b>1,300,810,463.76</b>	<b>1,093,233,854.88</b>
<b>TOTAL ASSETS</b>		<b>1,616,184,833.61</b>	<b>1,413,781,045.52</b>
<b>II EQUITY AND LIABILITIES</b>			
<b>EQUITY</b>			
a) Equity share capital	16	39,896,346.00	39,896,346.00
b) Other equity	17	390,805,832.93	373,316,851.80
<b>Total Equity</b>		<b>430,702,178.93</b>	<b>413,213,197.80</b>
<b>LIABILITIES</b>			
<b>Non-Current Liabilities</b>			
a) Financial liabilities			
i) Borrowings	18	291,108,196.45	114,958,423.25
b) Provisions	19	16,045,041.00	16,309,257.00
c) Other non - current liabilities		-	-
d) Deferred Tax Liability		13,770,757.00	9,406,562.00
<b>Total non current - liabilities</b>		<b>320,923,994.45</b>	<b>140,674,242.25</b>
<b>Current Liabilities</b>			
a) Financial liabilities			
i) Borrowings	20	105,295,261.98	234,063,992.35
ii) Trade and other payable	21	599,605,624.36	462,231,432.05
iii) Other financial liabilities	22	246,642.25	185,831.42
b) Provisions		-	-
c) Other current liabilities	23	148,155,926.64	137,724,991.65
d) Current tax liabilities (net)	24	11,255,205.00	25,687,358.00
<b>Total current liabilities</b>		<b>864,558,660.23</b>	<b>859,893,605.47</b>
<b>TOTAL EQUITY &amp; LIABILITIES</b>		<b>1,616,184,833.61</b>	<b>1,413,781,045.52</b>
Significant accounting policies	2		
The accompanying notes form an integral part of these Financial Statements			
Notes (Including Significant Accounting Policies) Forming Part of the Financial Statements	1		
The above Balance Sheet should be read in conjunction with the accompanying notes.			

As per our attached report of even date.

For Savla & Associates  
Chartered Accountants  
Firm Registration No - 109361W

Deepak G. Savla  
Partner  
Membership No - 043901  
UDIN No. :

Place - Mumbai  
Date :- 28th June 2021



For and on behalf of the Board of Directors of Fredun Pharmaceuticals Limited

CIN No - L24239MH1987PLC043662  
For Fredun Pharmaceuticals Limited

Dr. (Mrs) Daulat N. Medhora  
Joint Managing Director  
DIN : 01745277

MR. Fredun N. Medhora  
Managing Director & CFO  
DIN :01745348





FREDUN PHARMACEUTICALS LIMITED			
Standalone Statement of Profit and Loss for the year ended 31 March, 2021			
	Notes	As at 31 March, 2021	As at 31 March, 2020
<b>I Revenue</b>			
Revenue from Operations	25	1,315,518,666.92	1,102,985,701.22
Other Operating Revenue	26	23,414,501.46	24,727,889.49
Other income	27	13,966,032.67	5,171,307.88
<b>Total Income</b>		<b>1,352,899,201.05</b>	<b>1,132,884,898.59</b>
<b>II Expenses</b>			
Cost of materials consumed	28	1,006,041,327.39	861,179,102.90
Cost of materials consumed for R & D	29	4,738,786.00	6,722,396.00
Changes in inventories of raw materials, packing materials, stock in trade and wip	30	11,681,706.00	-50,427,405.00
Manufacturing & Service Cost	31	47,702,115.64	52,888,651.99
Employee benefit Exp.	32	86,560,981.61	89,476,744.02
Finance Cost	33	41,620,876.68	44,138,636.69
Depreciation and amortisation expense	34	20,037,450.34	18,787,338.70
Operating and other expenses	35	89,813,243.88	84,672,703.34
Payment to Auditors		1,000,000.00	500,000.00
Impairment loss / (reversal)			
<b>Total Expenses</b>		<b>1,309,196,487.54</b>	<b>1,107,938,168.64</b>
<b>III Profit before exceptional items and tax</b>		<b>43,702,713.51</b>	<b>24,946,729.95</b>
Exceptional Items		11,636,869.51	-
<b>IV Profit before tax from continuing operations</b>		<b>32,065,844.00</b>	<b>24,946,729.95</b>
<b>V Tax Expenses:</b>			
Current Tax		7,555,000.00	4,439,400.00
Deferred Tax		4,364,195.00	1,488,146.00
<b>VI Profit for the year from continuing operations</b>		<b>20,146,649.00</b>	<b>19,019,183.95</b>
<b>VII Profit before tax from discontinued operations</b>		-	-
<b>VIII Tax expenses of discontinued operations</b>		-	-
<b>IX Profit for the year from discontinued operations</b>		-	-
<b>X Net Profit for the year</b>		<b>20,146,649.00</b>	<b>19,019,183.95</b>
<b>XI Other Comprehensive Income</b>			
<b>A Items that will not be classified to profit and loss</b>			
i) Re measurement of post - employment benefit obligations		-23,535.00	-
ii) Income tax related to items that will not be reclassified to profit and loss		-	-
<b>B Items that will be reclassified to profit and loss</b>		-	-
<b>XII Total Comprehensive Income for the year</b>		<b>20,123,114.00</b>	-
<b>XIII Earning per equity share (Face value of Rs. 10/- each)</b>	36		
Earning per equity share of continuing operations		5.05	4.77
Basic and diluted (in Rs.)			
Earning per equity share of discontinued operations		-	-
Basic and diluted (in Rs.)		-	-
Earning per equity share of continuing and discontinued operations		5.05	4.77
Basic and diluted (in Rs.)			
Significant accounting policies	2		
The accompanying notes form an integral part of these Financial Statements			

As per our attached report of even date.

For Savla & Associates  
Chartered Accountants  
Firm Registration No - 043901

Deepak G. Savla  
Partner  
Membership No - 043901  
UDIN No. : 21043901AAAAFF8104

Place - Mumbai  
Date :- 28th June 2021



For and on behalf of the Board of Directors of  
Fredun Pharmaceuticals Limited

CIN No - L24239MH1987PLC043662  
For Fredun Pharmaceuticals Limited

Dr. (Mrs) Daulat N. Medhora  
Joint Managing Director  
DIN : 01745277

MR. Fredun N. Medhora  
Managing Director & CEO  
DIN : 01745348

